Get the Stockscreener App
11.64
4.02%
0.45
Valneva Se Adr stock is traded at $11.64, with a volume of 48,007.
It is up +4.02% in the last 24 hours and up +86.84% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
See More
Previous Close:
$11.19
Open:
$11.83
24h Volume:
48,007
Relative Volume:
0.79
Market Cap:
$990.50M
Revenue:
$163.13M
Net Income/Loss:
$-34.75M
P/E Ratio:
-22.59
EPS:
-0.5152
Net Cash Flow:
$-231.66M
1W Performance:
+0.95%
1M Performance:
+86.84%
6M Performance:
+56.45%
1Y Performance:
+52.16%
1-Day Range:
$11.46
$11.91
1-Week Range:
$11.18
$12.25
52-Week Range:
$3.62
$12.25
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
11.64 | 1.03B | 163.13M | -34.75M | -231.66M | -0.5152 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
Valneva (NASDAQ:VALN) Coverage Initiated by Analysts at HC Wainwright - Defense World
Short Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Expands By 91.2% - Defense World
Valneva (NASDAQ:VALN) Trading Up 14.3% After Better-Than-Expected Earnings - Defense World
Valneva (NASDAQ:VALN) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Valneva SE earnings beat by $0.22, revenue topped estimates - Investing.com
Valneva (NASDAQ:VALN) Trading Down 6.7% – Here’s What Happened - Defense World
Valneva (NASDAQ:VALN) Sets New 1-Year High – Still a Buy? - Defense World
European ADRs Tick Up As Healthcare And Industrials Shine - Finimize
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées et une mise à jour des caractéristiques du produit - GlobeNewswire Inc.
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock? - Yahoo Finance
[Valneva SE] Declaration of shares and voting rights - GlobeNewswire Inc.
Valneva SE earnings missed by $0.01, revenue topped estimates - Investing.com
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
Valneva SE Company Investigated by the Portnoy Law Firm - GlobeNewswire
Valneva shares leap on Brazilian approval of chikungunya vaccine By Investing.com - Investing.com India
Valneva shares leap on Brazilian approval of chikungunya vaccine - Investing.com Australia
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
VALN Doses First Infant With Shigella Vaccine In Mid-Stage Study - Barchart.com
H.C. Wainwright maintains Buy on Valneva with $17 price target - Investing.com
Valneva SE ADR’s Banking’s 100-Day Moving Average at 5.61: Will the Stock Break Through? - investchronicle.com
The Schall Law Probes Valneva Over Vaccine Safety Concerns - Lawyer Monthly
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm - Business Wire
Valneva SE earnings missed by $0.32, revenue fell short of estimates - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - markets.businessinsider.com
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):